Cardiovascular status following combined angiotensin-converting enzyme and AT1 receptor inhibition in conscious spontaneously hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 30, Issue 5-6, 2003, Pages 317-323

  Duke, Lisa M ^a   Paull, Jeremy R A ^a   Widdop, Robert E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Angiotensin II; Angiotensin converting enzyme inhibitor; AT1 receptor antagonist; Blood pressure; Cardiac hypertrophy; Spontaneously hypertensive rats; Vascular hypertrophy

Indexed keywords

ACETYLCHOLINE; ALBUMIN; ANGIOTENSIN; ANGIOTENSIN I; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MACROGOL; PERINDOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DRUG EFFECT; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR PHYSIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 0037795242     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2003.03837.x     Document Type: Article

References (43)

1. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986; 8: 553-9.
2. Timmermans PB, Wong P, Chiu A et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 1993; 45: 206-51.
3. Levy BI. The potential role of angiotensin II in the vasculature. J. Hum. Hypertens. 1998; 12: 283-7.
4. Unger T. The role of the renin-angiotensin system in the development ofcardiovascular disease. Am. J. Cardiol. 2002; 89 (Suppl.): A3-10.
5. Lundie ML, Friberg P, Kline RL, Adams MA. Long-term inhibition of the renin-angiotensin system in genetic hypertension: Analysis of the impact on blood pressure and cardiovascular structural changes. J. Hypertens. 1997; 15: 339-48.
6. Campbell DJ, Kladis A, Valentinjn AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J. Cardiovasc. Pharmacol. 1995; 26: 233-40.
7. Azizi M, Chatellier G, Guyene T, Murieta-Geoffroy D, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825-34.
8. Menard J, Campbell DJ, Azizi M, Gonzales M. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997; 96: 3072-8.
9. Webb RL, Navarrete AE, Davis S, De Gasparo M. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J. Hypertens. 1998; 16: 843-52.
10. Rodrigo E, Maeso R, Munoz-Garcia R et al. Endothelial dysfunction in spontaneously hypertensive rats: Consequences of chronic treatment with losartan or captopril. J. Hypertens. 1997; 15: 613-18.
11. Schiffrin EL, Park JB, Intengan HD, Touyz R. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
12. Bennett MA, Hillier C, Thurston H. Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: Effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine. J. Hypertens. 1996; 14: 389-97.
13. Hirata Y, Hayakawa H, Kakoki M et al. Nitric oxide release from kidneys of hypertensive rats treated with imidapril. Hypertension 1996; 27: 672-8.
14. Paull JRA, Widdop RE. Persistant cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. J. Hypertens. 2001; 19: 1393-402.
15. Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 1999; 34: 1112-16.
16. Widdop RE, Li XC. A simple versatile method for measuring tail cuff systolic blood pressure in conscious rats. Clin. Sci. 1997; 93: 191-4.
17. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res. 1977; 41: 19-26.
18. Cooper ME, Allen TJ, Jerums G, Doyle AE. Accelerated progression of diabetic nephropathy in the spontaneously hypertensive streptozotocin diabetic rat. Clin. Exp. Pharmacol. Physiol. 1986; 13: 655-62.
19. Cooper ME, Rumble JR, Gin T, Lim-Joon T. Diabetic renal microvascular disease: The role of hypertension and ACE inhibitors. Clin. Exp. Pharmacol. Physiol. 1992; 19: 23-7.
20. Stergiou GS, Skeva II, Baibas NM et al. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J. Cardiovasc. Pharmacol. 2000; 35: 937-41.
21. Nunez E, Hosoya K, Susic D, Frohlich ED. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997; 29: 519-24.
22. Morgan T, Griffiths C, Delbridge L. Interaction of ACE inhibitors and AT(1)-receptor blockers on maximum blood pressure response in spontaneous hypertensive rats. J. Renin-Angiotensin-Aldosterone Syst. 2002; 3: 16-18.
23. 1 angiotensin-receptor blockade on structure and function of small arteries in SHR. J. Cardiovasc. Pharmacol. 1997; 30: 75-83.
24. Rizzoni D, Porteri E, Piccoli A et al. Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension 1998; 32: 305-10.
25. Zolk O, Flesch M, Schnabel P et al. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2) 27 rats. Br. J. Pharmacol. 1998; 123: 405-12.
26. Sanada S, Kitakaze M, Node K et al. Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats. Hypertension 2001; 38: 404-11.
27. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin. Exp. Pharmacol. Physiol. 1996; 3 (Suppl.): S125-31.
28. Gillies LK, Werstiuk ES, Lee RMKW. Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension. J. Hypertens. 1998; 16: 477-86.
29. Gohlke P, Stoll M, Lamberty V et al. Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. J. Hypertens. 1992; 10 (Suppl. 10): S141-4.
30. Kim S, Yoshiyama M, Izumi Y et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 103: 148-54.
31. Izzo JI, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35: 1021-4.
32. Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br. J. Pharmacol. 2000; 131: 138-44.
33. Mckelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study the RESOLVD pilot study investigators. Circulation 1999; 100: 1056-64.
34. Kansui Y, Fujii K, Goto K, Abe I, Iida M. Angiotensin II receptor antagonist improves age-related endothelial dysfunction. J. Hypertens. 2002; 20: 439-46.
35. Goto K, Fujii K, Onaka U, Abe I, Fujishima M. Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 2000; 36: 575-80.
36. Rumble JR, Doyle AE, Cooper ME. Comparison effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes. Am. J. Hypertens. 1995; 8: 53-7.
37. Isogai S, Kameyama M, Iso K, Yoshino G. Protective effects of a small dose of captopril on the reduction of glomerular basement membrane anionic sites in spontaneously hypertensive rats with streptozotocin-induced diabetes. J. Diabetes Complications 1998; 12: 170-5.
38. Wienen W, Richard S, Champeroux P, Audeval-Gerard C. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J. Renin-Angiotensin-Aldosterone Syst. 2001; 2: 31-6.
39. Nakamura Y, Ono H, Zhou X, Frohlich ED. Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in Nω-nitro-L-arginine methyl ester/spontaneously hypertensive rats. Hypertension 2001; 37: 1262-7.
40. Ferrari P, Marti H, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J. Hypertens. 2002; 20: 125-30.
41. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin. Sci. 2001; 100: 591-9.
42. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol. Dial. Transplant. 2002; 17: 1019-24.
43. Weber M. Angiotensin II receptor blockers and cardiovascular outcomes: The evidence now and in the future. J. Renin-Angiotensin-Aldosterone Syst. 2001; 2 (Suppl. 2): S12-16.